Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

FDA grants accelerated approval to epcoritamab for relapsed/refractory follicular lymphoma

On June 26, 2024, the U.S. Food and Drug Administration (FDA) approved epcoritamab for the treatment of adult patients with…

Read More

FDA approves first-in-class telomerase inhibitor imetelstat for transfusion-dependent LR-MDS

On June 6, 2024, the U.S. Food and Drug Administration (FDA) approved imetelstat for adults with low- to intermediate-1 risk…

Read More

Practical considerations for CAR-T therapy in hematological malignancies

Read More

FDA approves fidanacogene elaparvovec, a one-time gene therapy, for adult patients with hemophilia B

On April 26, 2024, the U.S. Food and Drug Administration (FDA) granted approval to fidanacogene elaparvovec, a one-time gene therapy,…

Read More

FDA approves cilta-cel for adult patients with R/R multiple myeloma after at least one prior line of therapy

On April 5, 2024, the U.S. Food and Drug Administration (FDA) granted approval to ciltacabtagene autoleucel (cilta-cel), a B-cell maturation…

Read More

Case Study: CLL diagnosis, prognostication, and treatment

In this exclusive case study, leading hemonc experts Sanam Loghavi and Matthew Davids discuss the current approach to the diagnosis,…

Read More

Case Study: diagnosis, classification and treatment of follicular lymphoma

In this exclusive case study, leading hemonc experts Sanam Loghavi and Loretta Nastoupil discuss the current approach to the diagnosis…

Read More

Case Study: AML diagnosis, classification, risk-stratification and treatment

Sanam Loghavi and Naval Daver, discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals